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Statement of translational relevance 
Non Melanoma Skin Cancer (NMSC) is the most common malignancy worldwide. 
Although surgery is a successful standard of care, it often brings disfiguration and 
pain to the patients. To investigate alternative treatment options like immunotherapy, 
we have shown for the first time that CT-antigens are expressed in over 50% of 
NMSC patients. These tumor antigens are absent from healthy tissues except testis 
and placenta and are currently under investigation as cancer vaccine targets in 
numerous clinical trials. 
Also, we present the novel finding that imiquimod upregulates MHC class I 
expression in BCC, which is accompanied by infiltrating CD8+ cells. 
Taken together these data can lead to new immunotherapy approaches of especially 
unresectable NMSC and open new application ranges for the immune response 
modifier imiquimod, which can possibly be translated to other malignancies. 
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Abstract 
 
Purpose: Non melanoma skin cancer (NMSC) is the most common cancer and 
comprises basal cell (BCC) and squamous cell carcinoma (SCC). The incidence of 
SCC increases drastically in immunosuppressed individuals, suggesting a critical role 
of the immune system in controlling SCC. To find an explanation for the selective 
immunosurveillance of SCC, we investigated the expression of cancer-testis antigens 
(CTA), MHC class I and the infiltration by immune cells in BCC and SCC. 
Experimental design: We determined the expression of 23 different CTA in 63 BCC 
and 40 SCC biopsies of immunocompetent and in 20 biopsies of immunosuppressed 
SCC patients by RT-PCR and immunohistochemistry.  IgG responses to 36 tumor 
antigens were measured by Western Blotting and ELISA. MHC-I expression and 
CD8+ T cell infiltration were analyzed by immunohistochemistry in BCC and SCC of 
immunocompetent and immunosuppressed patients and in imiquimod-treated BCC 
patients. 
Results: We found expression of at least one CTA in 81% of BCC and in 40% of 
SCC. We did not detect CTA-specific serum IgG. Most SCC, but not BCC, expressed 
MHC-I and were infiltrated with CD8+ cells. Imiquimod-treated BCC expressed MHC-I 
and were infiltrated by CD8+ T cells. 
Conclusions:  We propose that immunosurveillance controls SCC, but not BCC, as 
the latter lacks MHC-I. This fits with the increased incidence of SCC in 
immunosuppressed individuals and may explain the relatively low prevalence of CT-
antigen expression in SCC as a result of CD8+ T cell driven immunoediting. 
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Introduction 
 
Non melanoma skin cancers (NMSC) are the most common cancers in the 
Caucasian population and include squamous (SCC) and basal cell carcinoma (BCC). 
According to the WHO, 2-3 million new cases of NMSC occur globally each year1. 
NMSC presents a low metastatic potential, however, the tumor can cause substantial 
local damage if not treated early. The standard surgical care of SCC and BCC often 
causes severe pain and disfiguration (recently reviewed in (1)).  
The risk to develop NMSC significantly increases up to 250 fold in 
immunosuppressed patients, such as organ transplant recipients (OTR). In addition, 
aggressive and metastatic variants of SCC develop in OTR, which represent a critical 
health burden (2, 3). The ratio BCC:SCC is 4:1 in immunocompetent patients, but 
1:10 or higher in OTR, suggesting a critical role for immunosurveillance in SCC but 
not in  BCC. However, studies explicitly addressing this issue are lacking.  
Although NMSCs are frequently infiltrated by immune cells (for review see (4)), the 
immune system often seems incapable of eradicating the tumor. Downregulation of 
E-Selectin and recruitment of regulatory T cells (T reg) (5) as well as malfunctioning 
intratumoral myeloid dendritic cells (6) have been proposed as mechanisms that 
compromise local tumor-specific immunity in SCC. In the case of BCC, MHC-I 
absence or down-regulation (7, 8) and the presence of T regs (9) was observed.  
Immunotherapy is an alternative treatment approach, especially for cancers that can’t 
be surgically removed due to their site or to multiple metastases. Usually, patients 
are immunized with tumor-associated antigens in order to induce or boost tumor-
specific immunity and this approach has shown objective clinical responses in some 
patients. Many of those vaccines contain tumor-specific differentiation antigens 
                                                 
1 http://www.who.int/uv/faq/skincancer/en/index1.html 
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(Melan-A/MART-1, tyrosinase, gp100 in the case of melanoma), overexpressed 
antigens (e.g. p53, survivin) or cancer-testis (CT) antigens (e.g. NY-ESO-1, members 
of the MAGE family) (10, 11). CT-antigens belong to an extended family of antigens 
that are expressed by a large variety of malignancies and that are absent from 
healthy tissue except for testis and placenta. In addition, cancer patients often 
develop spontaneous immune responses towards CT-antigens, which illustrates their 
immunogenicity (for review see (12)). In contrast to other malignancies including 
melanoma, tumor-specific immune responses and tumor-associated antigens that 
may be the target of such responses are scarcely investigated in NMSC and as a 
consequence, it is unknown whether immunotherapy may be a suitable therapeutic 
modality for these cutaneous malignancies. In a recent study, the expression of the 
CT-antigen MAGE-A4 was identified in cutaneous SCC on an immunohistochemical 
level (13), but no other data regarding the expression and immunogenicity of CT-
antigens in BCC and SCC are available. 
In this paper we present the first wide screening for CT-antigen expression in SCC 
and BCC in immunocompetent and –suppressed (OTR) patients. Furthermore, when 
comparing BCC and SCC with respect to MHC class I expression and infiltration by 
CD8+ T cells, we found that both immunologically relevant parameters were 
significantly lower in BCC. This may offer an explanation for the selective increase of 
SCC-incidence in OTR. 
Topical application of imiquimod, a Toll-like receptor (TLR) 7 agonist, results in total 
regression of the lesion in a large proportion of NMSC patients. Interestingly, we 
found a significant upregulation of MHC class I expression in BCC upon imiquimod 
treatment, which adds another possible mode of action to the presumed ones, 
including stimulation of innate immunity and the induction of apoptosis in tumor cells 
(14, 15).  
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Materials and Methods 
 
Patient samples 
 
All patients enrolled in the study were treated at the Dermatology Department of the 
University Hospital of Zurich. The study was approved by the cantonal ethics 
committee (EK No. 1017). All patients signed informed consent. Specimens of 
patients receiving imiquimod treatment had been published previously (15, 16). 8 
patients were analyzed, which applied 5% imiquimod cream (Aldara, 3M 
Pharmaceuticals, Saint Paul, MN) once daily 5 times per week for a maximum of 6 
weeks. Patients were evaluated weekly until the tumor began to show signs of 
erosion. At this point, the tumor was surgically excised and stored in formalin.  
For PCR extraction, primary cutaneous SCC (including the non-invasive forms actinic 
keratosis and morbus bowen to represent the whole facet of the disease), BCC and 
healthy skin samples were obtained during MOHs micrographic surgery and frozen in 
liquid nitrogen. We obtained 113 biopsies from immunocompetent patients (Suppl. 
table 1) and 20 SCC biopsies from organ transplant recipients receiving 
immunosuppressive treatment (Suppl. table 2), histological classification was done 
according to (17). 
From 23 immunocompetent BCC and 2 OTR BCC and 8 immunocompetent SCC and 
1 OTR SCC patients, serum was collected. 
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Cell culture 
 
BCC biopsies were minced into pieces ≤ 2mm2 and digested in Collagenase type IV 
(Sigma-Aldrich, St. Louis, MO) for 1-2hrs at 37°C. Fragments were digested with 
0.25% Trypsin (Invitrogen, Carlsbad, CA) for 15-30 min. Debris was filtered through 
100μm and 40 μm nylon filters (BD Biosciences, San Jose, CA) and single cells were 
cultured in Keratinocyte SFM Medium (Invitrogen, Carlsbad, CA) with 0.5U/ml 
Penicillin (Invitrogen, Carlsbad, CA) and 0.5μg/ml Streptomycin (Invitrogen, Carlsbad, 
CA). Upon reaching confluency, cells were trypsinized and cultured as described 
above. 
 
In vitro imiquimod and IFN-γ treatment 
BCC short-term cultures (passage 1) were incubated in Keratinocyte SFM Medium 
(Invitrogen, Carlsbad, CA) containing either 100U/ml IFN-γ (Pepro Tech Inc., Rocky 
Hill, NJ) or 30μM imiquimod (Aldara Crème 5%, MEDA Pharma, Wangen-Brütisellen, 
Switzerland) for 36 hours at 37°C.  
 
Flow cytometry  
Samples were stained with FITC-anti-β2-microglobulin, APC-anti-HLA-A,B,C (BD 
biosciences, San Jose, CA)  and LIVE/DEAD violet fixable dead cell stain kit 
(Invitrogen, Carlsbad, CA). Samples were measured on a Cyan ADP (Beckman 
Coulter, Fullerton, CA) and analyzed with Flow Jo Software (Tree Star, Ashland, OR). 
 
RNA isolation and reverse transcription PCR (RT-PCR) 
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Total RNA/DNA extraction from frozen samples was performed using the AllPrep 
DNA/RNA Mini Kit (Quiagen, Valencia, CA) and RNA was subjected to DNAse I 
digestion (Invitrogen, Carlsbad, CA). Total RNA concentration and purity was 
evaluated using the NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). 150 ng of RNA were transcribed using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosciences, Foster City, CA). 
RT-PCR was carried out using Taq DNA Polymerase (NEB, Ipswich, MA) with 
primers specific for the individual CT-antigens or for β-actin as internal control 
(Supplementary table 3). The cDNA samples were amplified using an Eppendorf 
Mastercycler Gradient (Eppendorf AG, Hamburg, Germany) using the following 
conditions: An initial denaturation step for 10 min at 95°C, 35 amplification cycles 
(denaturation for 1 min at 95°C, annealing for 1 min at variable temperatures 
(Supplementary table 3), elongation for 1 min at 72°C) and a final elongation step for 
10 min at 72°C. All primers were tested on at least five independent control healthy 
skin samples. All kits were used according to manufacturers’ recommendations. 
 
Immunohistochemistry 
 
Paraffin embedded tissue sections were stained with mouse-anti human monoclonal 
antibodies against CD8 (1:100; DAKO A/S, Glostrup, Denmark), CD56 (1:50; 
Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), CT-45/KiA10 (1:50, 
generous gift from H. J. Heidebrecht, University of Kiel, Germany), MAGE-A1 (1:200, 
generous gift from the Ludwig Institute for Cancer Research, New York, NY), MHC-I 
(1:1000, RDI Research Diagnostics, Inc., Concord, MA), NY-ESO-1 (1:50, ZYMED 
Laboratories Inc., South San Francisco, CA), rabbit-anti-human polyclonal antibody 
against PRAME (5μg/ml, Abcam limited, Cambridge, MA) and the mouse hybridoma 
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supernatant 57B (13) that predominantly recognizes MAGE-A4 (undiluted, generous 
gift by Prof. Giulio C. Spagnoli, Department of Surgery, University Hospital Basel, 
Switzerland). Primary antibodies were detected using the ultraVIEW DAB detection 
kit (Ventana Medical Systems, Tucson, AZ). Sections were counterstained with 
hematoxylin, dehydrated and mounted. All sections were stained with the Ventana 
Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ) 
using Ventana reagents for the entire procedure.  
 
Image analysis and quantification 
 
Images of the stained paraffin sections were acquired on a Zeiss Axiophot HAL100 
(Carl Zeiss MicroImaging GmbH, Göttingen, Germany) with the KYF70 digital camera 
(JVC, Yokohama, Japan) and the software analySISˆD (Olympus, Tokyo, Japan). 
Adobe Photoshop Version 10.0 (Adobe systems incorporated, San Jose, CA) was 
used for image analysis. 
Intensity of immunoreactivity was scored in arbitrary units as negative (0), weakly (1), 
moderately (2) or strongly (3) positive as illustrated in Figure S1. This panel of figures 
was compiled before the systematic evaluation of the tumor cohort was commenced 
and served as reference. Quantification of CD8+ cells present in intra- and 
peritumoral regions as well as invasive front were acquired counting cells in high 
power fields (HPF) of 40x magnification. In case of a heterogeneous histology, up to 
3 HPF were counted and the average is displayed in the figures. A pathologist 
advised on and supervised the evaluation of immunohistochemistry. 
 
Western blot analysis 
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We tested sera from 34 patients for the presence of CT-antigen specific IgG by 
Western Blotting as described (18), using the recombinant proteins CT-45, NY-ESO-
1 and PRAME. All proteins were overexpressed in E. coli, NY-ESO-1 was produced 
as previously described (18), CT-45 was a generous gift from H. J. Heidebrecht, 
University of Kiel, Germany and PRAME was a generous gift from C. Melief, 
University of Leiden Medical Center, The Netherlands. 
 
ELISA 
 
ELISA screening was carried out as recently described (Gnjatic et al., 2009). 34 
NMSC sera were screened for the presence of IgG specific responses for 36 different 
tumor antigens (for detailed list of antigens see Fig. S2). 
 
Statistical analysis 
 
Statistical analysis was performed with SPSS, version 17.0 (SPSS Inc, Chicago, IL, 
USA). P values < 0.05 were considered significant. The t-Test, Wilcoxon Test, 
Fisher´s Exact Test and Pearsons Correlations were used for analysis, depending on 
the data set.  
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Results and Discussion 
 
CT-antigens are broadly expressed in non-melanoma skin cancer (NMSC) 
 
We investigated expression of 23 CT-antigens in biopsies from 113 
immunocompetent NMSC patients and 13 corresponding healthy tissues with reverse 
transcription PCR (RT-PCR) and immunohistochemistry.  
Overall, CT-antigens were broadly expressed in NMSC on the mRNA level, PRAME 
was the most frequently expressed antigen with 55% overall expression in NMSC, 
followed by MAGE-A4 (25.6%), MAGE-A9 (23.9%) and NY-ESO-1 (14.2%). We 
found no expression of non-X chromosome-linked CT-antigens like Boris or BRDT 
(Figure 1) and no expression of any CT-antigen in the healthy skin samples.  
We did not observe any difference in CT-antigen expression between non-invasive 
and invasive SCC, hence the various histological types are presented together as 
one group (SCC) in all the figures.  
Analysis of CT-antigen expression by immunohistochemistry on paraffin sections 
confirmed our RT-PCR results in all cases investigated (Figure 1C). Most CT-
antigens were homogeneously expressed within the entire tumor, however, the 
expression of MAGE-A4 and PRAME varied in expression intensity between patients 
and often a stronger staining was observed in cells detaching from the tumor 
structure, so-called acantholytic cells (Figure 1C). 
CT-antigens are frequently co-expressed in various malignancies (19-21). Our results 
in non-melanoma skin cancer confirmed these observations, as over 40% of NMSC 
biopsies co-expressed ≥2 antigens and we observed examples of co-expression of 
as much as 11 antigens (Figure 2C). 
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All CT-antigens were more frequently expressed in BCC than in SCC, except for 
MAGE-A3 (Fig. 1B). In addition, BCC expressed more antigens per biopsy on 
average than SCC (Figure 2). The ratio of SCC to BCC in patients is usually 1:4, 
which means that BCC represents 80% of non-melanoma skin cancer and SCC 
represents 20%. However, in patients under immunosuppressive treatment (OTR), 
the ratio of SCC to BCC is reversed to be 10:1, meaning that BCC represents only 
approximately 10% of non-melanoma skin cancer in this population of patients, 
whereas over 90% are SCC. This makes SCC the most common cutaneous 
malignancy in OTR (3, 22), suggesting a role for adaptive immunity in the control of 
SCC. Immunological pressure in SCC may explain why the percentage of CT-
antigen+ biopsies as well as the number of CT-antigens per biopsy is lower in SCC 
compared to BCC (23).  However, we did not observe a significant difference in CT-
antigen mRNA expression in SCC from immunocompetent patients compared to 
SCC from OTR, with respect to the number of CT-antigens per biopsy or to the 
percentage of biopsies expressing 1 or more CT-antigens (Figure 3). This 
observation had previously been made for MAGE-A4 (13). This finding may be 
unexpected at first glance, but may be explained as follows: The majority of OTR 
develop SCC within the first 5 years after start of immunosuppressive treatment (3), 
which argues against de novo formation of the disease and in favor of uncontrolled 
outgrowth of subclinically preexisting malignancies. Before immunosuppressive 
treatment removed immunological control and allowed pathogenic outgrowth of the 
malignancy, subclinically existing SCC were presumably subjected to immunological 
pressure, resulting in selective outgrowth of tumors that express fewer CT-antigens. 
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No spontaneous humoral immune responses to CT antigens in NMSC patients 
 
CT-antigens often cause spontaneous humoral responses in patients with cutaneous 
malignancies like melanoma (18, 24) and cutaneous T-cell lymphoma (25).  We used 
western blotting and ELISA to investigate whether also NMSC patients display 
humoral immune responses to tumor antigens. 
 We screened 34 sera from NMSC patients (9 SCC, 25 BCC) for antibodies against 
an array of CT-antigens by western blot (data not shown) and ELISA (Figure S2). 
The absence of tumor antigen-specific IgG in sera from patients with NMSC was in 
contrast with data from most other malignancies and was therefore unexpected. We 
explain the virtual absence of tumor-specific humoral immune responses by the 
relatively small tumor load of NMSC in comparison to other tumor entities. It has 
been well documented, that titers of tumor-specific IgG increase with progressive 
disease (26, 27) i.e. with increasing tumor load and/or the occurrence of metastases, 
both of which are rare in NMSC.  
 
Low expression of MHC class I and paucity of infiltrating CD8+ cells in BCC 
suggests limited immunosurveillance  
 
The selective increase of the SCC risk in immunosuppressed individuals suggests a 
more pronounced role of immunosurveillance in SCC than in BCC. One possible 
explanation may be the relative absence of suitable tumor-associated antigens in 
BCC, however, our results show the opposite (Fig 1-2). A relative absence of MHC 
class I molecules on BCC, which precludes recognition by CT-antigen-specific CD8+ 
effector T cells, may be another possibility. We thus compared the expression of 
MHC class I in BCC and SCC and correlated the amount of infiltrating CD8+ cells to 
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MHC-I expression by immunohistochemistry. We found that both the expression of 
MHC class I and the infiltration of the invasive front, peri- and intratumoral regions by 
CD8+ cells were drastically reduced in most BCC biopsies when compared to SCC 
biopsies (Fig. 4 and 5), which confirms previous observations (7, 8). Both the 
expression of MHC class I as well as the number of infiltrating CD8+ cells was most 
prominent in the invasive front of SCC biopsies and statistical analysis revealed a 
significant correlation between these two parameters (Fig. 5C). Thus, we propose 
that the relative absence of MHC class I molecules from tumor cells and the ensuing 
absence of infiltrating CD8+ cells in BCC makes this malignancy comparably resistant 
to the adaptive immune response. Natural killer cells were virtually absent from both 
BCC and SCC (assessed by CD56 staining, data not shown). 
Nevertheless, although MHC-I staining does not differ between SCC OTR and SCC 
patients, the number of CD8+ cells in the intra-, peri- and invasive regions of the 
tumor are decreased in SCC OTR compared to immunocompetent patients (Fig. 5B). 
This coincides with a recent study showing an overall decrease of cytotoxic T cells in 
OTR (28) and further outlines the role of CD8+-mediated immune control of SCC and 
probably not of BCC.  These results fit the fact that the activated sonic hedgehog 
pathway presumably is the driving force in BCC formation (for review see (29)) and 
that immunological tumor defence therefore has a minor impact on BCC formation.  
 
 
Local treatment with imiquimod results in upregulation of MHC class I  and 
increased peritumoral CD8+ T cell infiltration in BCC 
 
Repeated topical application of imiquimod, a TLR7-agonist, results in regression of 
superficial skin cancers, presumably through the induction of innate immunity and 
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apoptosis of tumor cells (14, 15). To investigate the possibility that imiquimod 
treatment impacts on the adaptive tumor-specific immune response, we compared 
the expression of MHC class I molecules and the presence of CD8+ T cells in BCC 
biopsies before and after imiquimod treatment.  
The expression of MHC class I by tumor cells was significantly stronger in biopsies 
after imiquimod treatment, which was accompanied by an increase of peritumoral 
CD8+ T cells (Fig. 6). As BCCs do not express TLR7 (30, 31), the observed 
upregulation of MHC class I molecules on tumor cells presumably is an indirect effect 
of imiquimod, which may be mediated through type I and type II interferons produced 
by infiltrating plasmacytoid dendritic cells (pDCs) (16) or by tumor stroma, or through 
stimulation of tumoricidal activity of inflammatory myeloid DCs and pDCs (32). Our 
assumption that up-regulation of MHC class I by imiquimod does not result from a 
direct interaction with BCC is supported by our observation that in vitro treatment of 
BCC cultures with 30μM imiquimod does not upregulate surface expression of HLA 
class I molecules. In contrast, treatment with IFN-γ (100U/ml) induced increased 
surface expression of β2-microglobulin as well as HLA-A,B,C molecules at least by 
two-fold (assessed by measuring mean fluorescence intensity by flow cytometry, data 
not shown). Alternatively, treatment with imiquimod may induce changes in the 
microenvironment other than upregulation of MHC class I molecules that support 
local tumor-specific CD8+ T cells, as has been reported for SCC (5, 33).  As the CD8+ 
T cells of imiquimod-treated BCC patients remain in the peritumoral region and do 
not seem to penetrate the BCC nests (Fig. 6), their tumor-antigen specificity and anti-
tumor effector functions remain to be confirmed for BCC. 
 
Taken together, we found that BCC expresses no or low levels of MHC class I 
molecules, and that – probably as a result thereof – significantly lower numbers of 
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CD8+ immune effector cells infiltrate the tumor. We thus propose that BCC is less 
subjected to immunological pressure than SCC, and our finding that BCC express 
more immunogenic CT antigens as well as the fact that the incidence of SCC but not 
of BCC increases in individuals under immunosuppressive treatment support this 
hypothesis. Furthermore, we propose that the therapeutic effect of local imiquimod 
treatment may involve - besides stimulation of the innate defense and induction of 
tumor cell apoptosis - the upregulation of MHC class I on tumor cells and the 
concomitant influx of CD8+ cells. 
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Figure Legends 
 
Fig. 1. CT-antigen expression in biopsies from immunocompetent NMSC patients as 
determined by RT-PCR. 1A. Expression of investigated CT-antigens in total number 
of biopsies (n=113). 1B. Differential expression of antigens in BCC (n=73) and SCC 
(n=40).1C. CT-antigen expression of selected SCC and BCC samples as determined 
by immunohistochemistry.  
 
Fig. 2. CT-antigen expression in biopsies from immunocompetent NMSC patients as 
determined by RT-PCR. 2A. Average of CT-antigens expressed per biopsy. 2B. 
Percentage of patients expressing at least one CT-antigen. 2C. Co-expression of CT-
antigens in biopsies from immunocompetent NMSC patients (n=113). 
 
Fig. 3. CT-antigen expression in biopsies from immunocompetent (SCC) vs. 
immunosuppressed (SCC OTR) SCC patients as determined by RT-PCR. 3A. 
Percentage of patients expressing at least one CT-antigen. 3B. Average of CT-
antigens expressed per biopsy. 
 
Fig. 4. Immunohistochemical staining of MHC-I (A and B) and CD8 (C and D) on 
consecutive sections of BCC Z-T-468 (B and D) and SCC Z-T-509 (A and C). 
 
Fig. 5. Quantification of MHC class I expression and infiltration of CD8+ T cells in 
biopsies from NMSC patients by immunohistochemistry. 5A. Histology (H)-score of 
MHC-I in SCC, BCC, SCC of immunosuppressed organ transplant recipients (OTR) 
and BCC of OTR. 5B. Quantification of CD8+ counts per 40x high power field (HPF) 
in intra- and peritumoral regions and invasive front of SCC, BCC, SCC OTR and BCC 
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OTR. 5C. Correlation between H-score for MHC-I expression with CD8+ T cell counts 
per HPF in sections from immunocompetent SCC patients. 5D. Correlation between 
H-score for MHC-I expression with CD8+ T cell counts per HPF in sections from 
immunocompetent BCC patients.  
 
Fig. 6. Quantification of MHC class I expression and infiltration of CD8+ T cells in 
imiquimod-treated and non-treated BCC by immunohistochemistry. 6A. H-score of 
MHC-I staining in biopsies from BCC patients taken before (pre) and after (post) 
imiquimod treatment (n=7). 6B. Quantification of CD8+ counts per 40x high power 
field (HPF) in intra- and peritumoral regions of biopsies from BCC patients before 
(pre) and after (post) imiquimod treatment (n=8). 6C. MHC-I expression and 
correlating CD8+ infiltration in sections from one representative BCC patient before 
(pre) and after (post) imiquimod treatment. 
 
Fig. S1. IHC scoring sheet for MHC-I expression as used as a reference for 
expression analysis. Numbers 0-3 indicate intensity of staining as illustrated in the 
pictures. 
 
Fig. S2. Summary of antibody titers obtained in ELISA with 36 antigens. Titers 
depicted in bold: significant reaction (>100). Titers depicted in italics: sera tested only 
in screening phase. ¹ Sera considered „sticky“ and therefore non-specific. ² Sera from 
OTR. 
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